GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera AG (OTCPK:BFFTF) » Definitions » Cyclically Adjusted PB Ratio

Biofrontera AG (Biofrontera AG) Cyclically Adjusted PB Ratio : 1.40 (As of Jun. 23, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Biofrontera AG Cyclically Adjusted PB Ratio?

As of today (2024-06-23), Biofrontera AG's current share price is $22.68. Biofrontera AG's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $16.20. Biofrontera AG's Cyclically Adjusted PB Ratio for today is 1.40.

The historical rank and industry rank for Biofrontera AG's Cyclically Adjusted PB Ratio or its related term are showing as below:

BFFTF' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.52   Med: 6.32   Max: 259.34
Current: 0.59

During the past years, Biofrontera AG's highest Cyclically Adjusted PB Ratio was 259.34. The lowest was 0.52. And the median was 6.32.

BFFTF's Cyclically Adjusted PB Ratio is ranked better than
84.99% of 753 companies
in the Drug Manufacturers industry
Industry Median: 1.87 vs BFFTF: 0.59

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Biofrontera AG's adjusted book value per share data for the three months ended in Mar. 2024 was $6.174. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $16.20 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biofrontera AG Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Biofrontera AG's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofrontera AG Cyclically Adjusted PB Ratio Chart

Biofrontera AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 13.88 7.13 1.65

Biofrontera AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.22 3.78 2.39 1.65 1.40

Competitive Comparison of Biofrontera AG's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biofrontera AG's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biofrontera AG's Cyclically Adjusted PB Ratio falls into.



Biofrontera AG Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Biofrontera AG's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=22.68/16.2
=1.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biofrontera AG's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Biofrontera AG's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=6.174/125.0381*125.0381
=6.174

Current CPI (Mar. 2024) = 125.0381.

Biofrontera AG Quarterly Data

Book Value per Share CPI Adj_Book
201406 5.186 99.543 6.514
201409 2.551 99.823 3.195
201412 -0.019 99.543 -0.024
201503 -1.864 99.717 -2.337
201506 -3.320 100.417 -4.134
201509 -4.816 100.417 -5.997
201512 -3.334 99.717 -4.181
201603 -0.515 100.017 -0.644
201606 0.742 100.717 0.921
201609 -1.773 101.017 -2.195
201612 8.254 101.217 10.197
201703 6.560 101.417 8.088
201706 5.661 102.117 6.932
201709 2.801 102.717 3.410
201712 1.940 102.617 2.364
201803 11.857 102.917 14.406
201806 8.887 104.017 10.683
201809 6.638 104.718 7.926
201812 8.154 104.217 9.783
201903 6.676 104.217 8.010
201906 12.440 105.718 14.713
201909 6.844 106.018 8.072
201912 4.823 105.818 5.699
202003 2.054 105.718 2.429
202006 2.326 106.618 2.728
202009 -0.556 105.818 -0.657
202012 3.675 105.518 4.355
202103 10.809 107.518 12.570
202106 9.207 108.486 10.612
202109 6.624 109.435 7.568
202112 22.984 110.384 26.035
202203 11.668 113.968 12.801
202206 7.967 115.760 8.606
202209 5.678 118.818 5.975
202212 7.090 119.345 7.428
202303 5.945 122.402 6.073
202306 6.085 123.140 6.179
202309 4.878 124.195 4.911
202312 7.171 123.773 7.244
202403 6.174 125.038 6.174

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biofrontera AG  (OTCPK:BFFTF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Biofrontera AG Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Biofrontera AG's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biofrontera AG (Biofrontera AG) Business Description

Traded in Other Exchanges
Address
Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.